Multiple Sclerosis: Current Status and Strategies for the Future

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

HARDBACK
price:$57.95
add to cart

Rights & Permissions

Free PDF Access

Free Resources

Related Titles

Multiple Sclerosis: Current Status and Strategies for the Future (2001)
Institute of Medicine (IOM)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "6 Future Strategies for Therapies." Multiple Sclerosis: Current Status and Strategies for the Future. Washington, DC: The National Academies Press, 2001.

Please select a format:

Page
324


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Page 324

111. Waisman A, Ruiz PJ, Hirschberg DL, et al. 1996. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat Med.; 2: 899-905.

112. Warrington AE, Asakura K, Bieber AJ, et al. 2000. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A.; 97: 6820-6825.

113. Waubant E, Goodkin D. 2000. Methodological problems in evaluating efficacy of a treatment in multiple sclerosis. Pathol Biol (Paris).; 48: 104-13.

114. Webster HD. 1997. Growth factors and myelin regeneration in multiple sclerosis. Mult Scler.; 3: 113-20.

115. Wicker LS, Miller BJ, Chai A, Terada M, Mullen Y. 1988. Expression of genetically dete mined diabetes and insulitis in the nonobese diabetic (NOD) mouse at the level of bone marrow-derived cells. Transfer of diabetes and insulitis to nondiabetic (NOD X B10) F1 mice with bone marrow cells from NOD mice. J Exp Med.; 167: 1801-10.

116. Wilson DB, Golding AB, Smith RA, et al. 1997. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol.; 76: 15-28.

117. Xu XM, Guenard V, Kleitman N, Aebischer P, Bunge MB. 1995. A combination of BDNF and NT-3 promotes supraspinal axonal regeneration into Schwann cell grafts in adult rat thoracic spinal cord. Exp Neurol.; 134: 261-72.

118. Yandava BD, Billinghurst LL, Snyder EY. 1999. “Global” cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. Proc Natl Acad Sci U S A.; 96: 7029-34.

119. Ye P, D'Ercole AJ. 1999. Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury. Endocrinology.; 140: 3063-72.

120. Zhang J, Stinissen P, Medaer R, Truyen L, Raus J. T-cell vaccination for the treatment of multiple sclerosis. In Zhang J, ed. Immunotherapy in Neuroimmunologic Diseases. London, England: Martin Dunitz; 1998.